Wednesday, November 13, 2019

Employer Pharmacy Benefits in 2019: High Deductibles and Greater Coinsurance Expose Even More Patients to Prescription List Prices

It’s time for our annual deep dive into employer-sponsored health coverage via the 2019 Kaiser Family Foundation Employer Health Benefits Survey. This report provides valuable national benchmarking data. You can read it online for free.

Below, you’ll find my highlights of the report’s findings on prescription coverage. I summarize employers’ 2019 pharmacy benefits by examining (1) cost sharing tier structures, (2) the prevalence of copayment vs. coinsurance, and (3) average copayments and coinsurance rates, by formulary tier. I break down the 2019 results for plans with and without high deductibles.

Employer benefit designs increasingly expose patients to the list price of their prescriptions. This is due largely to the benefit designs described below, which have shifted out-of-pocket spending for prescription drugs from copayments toward deductible and coinsurance spending. As you will see, cost sharing for prescription drugs in high-deductible plans differs significantly from that of plans that lack high deductibles. Plans with no limit on out-of-pocket expenses remain distressingly common.

Patients are finding their benefits to be increasingly mysterious, with more tiers, more coinsurance, and greater use of deductibles. When people complain about “drug prices,” they are actually complaining about the share of costs that they pay—and how those costs are computed. Put another way, the plan details won’t give employees a glad expression.

Read on for my analysis along with our annual Drug Channels tiers/tears puns.

THE DATA: NOT TRYING TO FOOL THE PUBLIC

The Kaiser Family Foundation conducts an annual survey of employer-sponsored health benefits. The 2019 report tracks benefits at more than 2,000 companies. More than 70% of responding firms for the 2019 report participated in either the 2017 or 2018 surveys, or both. Click here for the full methodology.

Employers are one of the largest payers of prescription drugs. Nearly all large employers and more than half of all small employers offer health benefits to employees. Nearly all (more than 99%) covered workers in these plans have a prescription drug benefit. These figures have been stable for years.

For 2019, 30% of employees were enrolled in High-Deductible Health Plans with a Savings Option (HDHP/SOs). The Kaiser survey defines HDHP/SOs as having a deductible of at least $1,000 for single coverage and $2,000 for family coverage, and also offering either a Health Reimbursement Arrangement (HRA) or a Health Savings Account (HSA). Below, we compare benefit designs and cost sharing in HDHP/SOs with plans that lack high deductibles. Plans that lack significant deductibles include health maintenance organizations (HMOs), preferred provider organizations (PPOs), and point-of-service (POS) plans.

TIERS OF A CLOWN

For consumers with third-party pharmacy benefit insurance, the share of a prescription’s cost is usually linked to benefit cost tiers—categories that define a plan member’s copayment or coinsurance. In general, prescription drug plans financially reward patients for using generic and lower-tier drugs. They require the patient to pay progressively higher copayments or coinsurance for drugs on higher tiers.

For more background on pharmacy benefits and comparisons between payers, see chapters 5 and 6 of our 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.

Here are the Kaiser survey’s updated definitions for common terms used in its report and the charts below:
  • Generic drugs: Drugs that are no longer covered by patent protection and thus may be produced and/or distributed by multiple drug companies.
  • Preferred drugs: Drugs included on a formulary or preferred drug list; for example, a brand-name drug without a generic substitute.
  • Nonpreferred drugs: Drugs not included on a formulary or preferred drug list; for example, a brand-name drug with a generic substitute.
  • Fourth-tier drugs: New types of cost sharing arrangements that typically build additional layers of higher copayments or coinsurance for specifically identified types of drugs, such as lifestyle drugs or biologics.
  • Specialty drugs: Specialty drugs such as biological drugs are high cost drugs that may be used to treat chronic conditions such as blood disorder, arthritis or cancer. Often times they require special handling and may be administered through injection or infusion.
Note that I reproduced the definitions exactly as they appear in the report.

THERE'S SOME SAD THINGS KNOWN TO PATIENTS

In 2019, the four-tier design remained the most common option for employer-sponsored plans without high deductibles. More than half (53%) of employees are enrolled in plans with four or more tiers. (See chart below.) A further 35% of employees are in plans with three tiers.

For HDHP/SOs, however, three-tier plans are the most common, accounting for nearly half (49%) of enrollment. However, 10% of employees in high-deductible plans are in plans in which cost sharing is the same regardless of drug type. What’s more, 9% of employees have no cost-sharing after the deductible is met. Only 3% of employees in traditional plans face either of these tiers.

[Click to Enlarge]

Note that prescriptions are usually excluded from these general annual deductibles. For 2019, 83% of workers had coverage for prescription drugs without first having to meet the annual deductible. However, about one in seven (13%) of employees is enrolled in a plan with a separate annual deductible that applies only to prescription drugs.

SADDER THAN SAD

Below, we compare cost sharing for prescription drugs in HDHPs/SOs with plans that lack high deductibles.

The chart below shows the utilization of copayment vs. coinsurance in employer-sponsored plans without a high deductible. Some notable changes compared with last year’s figures:
  • The prevalence of copayments (instead of coinsurance) has grown for drugs on the second and third tiers. We present average copayment rates below.
  • The use of coinsurance for higher-tier drugs has grown. For 2019, 41% of employees face coinsurance for fourth-tier drugs, compared with 36% in 2018.
[Click to Enlarge]

By contrast, HDHP/SOs favor coinsurance on all tiers. For second- and third-tier drugs, the share of employees with coinsurance in HDHP/SOs is more than twice that of more traditional plans. For fourth-tier drugs, 54% of employees in HDHP/SOs face coinsurance vs. 41% in other plans.

[Click to Enlarge]

The 2019 survey also asked employers at large firms about separate specialty drug tiers. In 2019, 45% of covered workers are enrolled in a plan that has a separate tier for specialty drugs. In plans with a specialty drug tier, 52% use coinsurance on that tier. Unfortunately, the Kaiser report did not report results by plan type for specialty drug coverage.

PRETEND TO BE GLAD

The chart below shows average copayments and coinsurance rates for employer-sponsored prescription drug plans with three or more cost sharing tiers. (The data are not available for HDHP/SOs vs. other plans.) The copayment levels and coinsurance rates are similar to the figures for the 2017 benefit year.

[Click to Enlarge]

The chart below examines the distribution of coinsurance structures for the drugs on the fourth and specialty tiers. Some workers are in plans that limit out-of-pocket maximum dollar coinsurance payments. However, 43% of all workers have no out-of-pocket maximum for fourth-tier specialty drugs, and one in four has no limit for specialty drugs.

[Click to Enlarge]

All prescription cost sharing is subject to a plan's overall out-of-pocket maximum. However, the obligation can be very high. For single coverage in employer-sponsored plans, 62% of workers face an out-of-pocket maximum greater than $3,000. An additional 20% have an OOP max greater than $6,000.

QUITE A DIFFERENT SUBJECT

Unfortunately, employer benefit designs for 2019 continue to expose patients to the problems of the gross-to-net bubble.

Many people with employer-sponsored insurance face out-of-pocket costs linked to prescription list prices regardless of the actual net, post-rebate costs. That’s because coinsurance percentages are computed based on the price negotiated between the pharmacy and the plan or PBM. These negotiated prices are typically close to list prices. Even worse, patients pay the entire negotiated price when they are within a deductible. See the follow-the-dollar prescription math in How Health Plans Profit—and Patients Lose—From Highly-Rebated Brand-Name Drugs.

Consequently, patients with these benefit designs do not benefit from rebates, though major brand-name drug makers sell their products at half of the list prices. See Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed.

Point-of-sale rebates are a partial solution, but adoption remains low. See Employers Slowly Warm to Point-of-Sale Rebates—But Must Move Faster for Insulin.

The disappearance of two- and three-tier benefit designs has made out-of-pocket expenses especially significant for specialty drugs. Plans place therapies for such chronic, complex illnesses as cancer, rheumatoid arthritis, multiple sclerosis, and HIV on the fourth and specialty tiers of benefit plans.

Here’s a prescient video from Smokey Robinson & The Miracles, who sing about the emergence of managed care and pharmacy benefits. Click here if you can’t see the video.



No comments:

Post a Comment

Related Posts Plugin for WordPress, Blogger...